Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing

CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.